ABBOTT LABORATORIES 8K

Abbott agreed to pay approximately $670 million to settle the Gill case and related NEC litigation involving around 2,000 infants over its preterm infant formulas, while denying liability and continuing to face substantial remaining lawsuits.

On August 20, 2026, Abbott announced that it has entered into agreements with three law firms to resolve the Gill case—following a July 2024 $495 million jury verdict and a denied appeal—as well as necrotizing enterocolitis-related claims on behalf of approximately 2,000 additional infants concerning its specialty preterm infant formulas, for an aggregate settlement amount of about $670 million, which Abbott characterizes as a compromise of disputed claims without admission of liability and a step toward substantially resolving broader ongoing litigation that still includes roughly 1,700 lawsuits involving about 12,700 individual infants in federal and state courts.

Filing Facts

CIK

1800

Ticker

ABT

Form

8K

Source Type

sec

Accession

0001104659-26-099247

Alert Tier

8